<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340300</url>
  </required_header>
  <id_info>
    <org_study_id>11-009</org_study_id>
    <nct_id>NCT01340300</nct_id>
  </id_info>
  <brief_title>Exercise and Metformin in Colorectal and Breast Cancer Survivors</brief_title>
  <official_title>Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metformin is a medication that is commonly used in the treatment of diabetes. Recently small
      studies in cancer patients without diabetes suggest that metformin may benefit in lowering
      insulin levels. In those studies of patients with cancer but not diabetes, glucose (or sugar)
      levels in the blood are generally no lowered. Insulin and insulin-like growth factors affect
      the growth of cancer cells.

      This randomized study will compare different interventions; exercise, exercise and metformin,
      metformin alone, or a control arm. The investigators are not directly testing how either
      exercise or metformin affects your disease. The investigators are testing how they affect
      insulin levels in your body as well as other blood markers. The investigators believe that
      these blood tests may either be related to cancer recurrences or be an early sign of cancer
      recurrences and they are testing how both exercise and metformin may change those markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized into one of four groups: exercise training, exercise training and
      metformin, metformin alone, or control arm. All subjects will have lifestyle measurements,
      interviews regarding activity level, diet questionnaires, and blood tests.

      Subjects randomized to exercise training will participate in two supervised exercise sessions
      per week with an exercise physiologist for 3 months. They will also be asked to exercise on
      their own for up to an additional 120 minutes each week.

      Subjects randomized to exercise training and metformin will participate in two supervised
      exercise sessions per week and will take metformin. Metformin will be taken once daily for
      the first two weeks and then twice daily for 3 months.

      Subjects randomized to metformin will take metformin once daily for the first two weeks and
      then twice daily.

      Subjects on the control arm will receive a packet of educational information on nutrition and
      physical activity developed by the National Cancer Institute and American Cancer Society. In
      addition to education information, they will be offered two supervised sessions with an
      exercise physiologist as well as a pedometer 3 months after enrollment in the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fasting Insulin Level</measure>
    <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
    <description>Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting insulin levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Other Insulin-Related Biomarkers</measure>
    <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
    <description>Markers related to insulin and insulin-like growth factors (including insulin-like growth factor 1 [IGF-1], IGF binding protein-1 [IGFBP-1], IGF binding protein-3 [IGFBP-3], leptin) will be measured by a blood draw at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose Level</measure>
    <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
    <description>Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting Glucose level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting Glucose levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Body Composition by Treatment Arm - Weight</measure>
    <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
    <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Body Composition by Treatment Arm - BMI</measure>
    <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
    <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Body Composition by Treatment Arm - Waist to Hip Ratio</measure>
    <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
    <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exercise training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exercise training with exercise physiologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise training with metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exercise training with exercise physiologist with oral metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Educational information</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <description>Two supervised exercise sessions per week</description>
    <arm_group_label>Exercise training</arm_group_label>
    <arm_group_label>Exercise training with metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral metformin QD for two weeks, then BID</description>
    <arm_group_label>Exercise training with metformin</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational information</intervention_name>
    <description>educational information</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage I-III colorectal or breast cancer

          -  Undergone curative-intent complete surgical resection and completed all adjuvant
             therapy (if indicated) at least 2 months prior to enrollment

          -  Note: Breast cancer subjects on hormonal therapy or trastuzumab only therapy and
             colorectal cancer subjects on adjunctive therapies not considered cytotoxic
             chemotherapy (including those participating in CALGB 80702 receiving only
             celocoxib/placebo) are eligible.

          -  Participants will be allowed to receive concomitant adjuvant endocrine therapy for
             breast cancer; however, all endocrine agents must be initiated at least 1 month prior
             to enrollment in the study and continued throughout the duration of study
             participation.

          -  Less than 120 minutes of exercise per week

          -  Approval by oncologist or surgeon

          -  English speaking and able to read English

          -  No planned surgery anticipated in the 3 month intervention period

          -  At least one month from any major surgery to start of intervention including colostomy
             reversal

        Exclusion Criteria:

          -  Concurrent other malignancy or history of other malignancy treated within the past 3
             years (other than non-melanoma skin cancer or in-situ cervical cancer)

          -  Metastatic disease

          -  Scheduled to receive any form of further adjuvant cancer therapy

          -  Currently on medication for diabetes treatment

          -  Pregnant or breast-feeding

          -  Any condition associated with increased risk of metformin-associated lactic acidosis
             (prior renal failure or liver failure, history of acidosis of any type; habitual
             intake of 3 or more alcoholic beverages per day)

          -  Known hypersensitivity or intolerance to metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Meyerhardt, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <results_first_submitted>July 11, 2017</results_first_submitted>
  <results_first_submitted_qc>September 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2017</results_first_posted>
  <disposition_first_submitted>February 6, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 31, 2017</disposition_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey A. Meyerhardt, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Colorectal</keyword>
  <keyword>Breast</keyword>
  <keyword>Insulin</keyword>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In a phase 2 RCT, stage I-III CRC &amp; BC survivors at least 2 months from completing standard therapy were randomized. Major eligibility included absence of recurrence, absence of diabetes (glucose &lt; 160 (random) or &lt; 126 (fasting) mg/dl), and exercising &lt; 120 min/wk. 1,426 patients screened, and 139 enrolled from September 2011 to December 2015.</recruitment_details>
      <pre_assignment_details>Stratification factors: BMI (&lt; 30 v &gt; 30), gender, tumor site (CRC v BC)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exercise Training With Metformin</title>
          <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
        </group>
        <group group_id="P2">
          <title>Exercise Training</title>
          <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
        </group>
        <group group_id="P3">
          <title>Metformin</title>
          <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
        </group>
        <group group_id="P4">
          <title>Control</title>
          <description>Educational information
Educational information: educational information</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline Blood Sample</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Follow-up Blood Sample</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated sickness, moving</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exercise Training With Metformin</title>
          <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
        </group>
        <group group_id="B2">
          <title>Exercise Training</title>
          <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
        </group>
        <group group_id="B3">
          <title>Metformin</title>
          <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
        </group>
        <group group_id="B4">
          <title>Control</title>
          <description>Educational information
Educational information: educational information</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="34"/>
            <count group_id="B5" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="48" upper_limit="58"/>
                    <measurement group_id="B2" value="58" lower_limit="49" upper_limit="65"/>
                    <measurement group_id="B3" value="55" lower_limit="49" upper_limit="61"/>
                    <measurement group_id="B4" value="56" lower_limit="48" upper_limit="66"/>
                    <measurement group_id="B5" value="55" lower_limit="48" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study Site</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>DFCI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Duke</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yale</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" lower_limit="25.5" upper_limit="34.2"/>
                    <measurement group_id="B2" value="28.5" lower_limit="26.4" upper_limit="32.8"/>
                    <measurement group_id="B3" value="28.8" lower_limit="25.3" upper_limit="33.9"/>
                    <measurement group_id="B4" value="28.4" lower_limit="25.5" upper_limit="31.9"/>
                    <measurement group_id="B5" value="28.5" lower_limit="25.6" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Location</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Breast Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Colorectal Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Stage</title>
          <description>Cancer is present. The higher the number, the larger the cancer tumor and the more it has spread into nearby tissues.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>stage I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stage II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown stage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Radiation Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fasting Insulin Level</title>
        <description>Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting insulin levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
        <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
        <population>11 patients are excluded for missing baseline blood samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise Training With Metformin</title>
            <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
          </group>
          <group group_id="O2">
            <title>Exercise Training</title>
            <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Educational information
Educational information: educational information</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin Level</title>
          <description>Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting insulin levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
          <population>11 patients are excluded for missing baseline blood samples.</population>
          <units>mU/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="1.07"/>
                    <measurement group_id="O2" value="-0.08" spread="1.06"/>
                    <measurement group_id="O3" value="-1.16" spread="1.18"/>
                    <measurement group_id="O4" value="2.79" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of insulin in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of insulin in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of insulin in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Insulin in combined arm is greater than the exercise-only or metformin-only arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Other Insulin-Related Biomarkers</title>
        <description>Markers related to insulin and insulin-like growth factors (including insulin-like growth factor 1 [IGF-1], IGF binding protein-1 [IGFBP-1], IGF binding protein-3 [IGFBP-3], leptin) will be measured by a blood draw at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
        <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
        <population>11 patients are excluded for missing baseline blood samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise Training With Metformin</title>
            <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
          </group>
          <group group_id="O2">
            <title>Exercise Training</title>
            <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Educational information
Educational information: educational information</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Other Insulin-Related Biomarkers</title>
          <description>Markers related to insulin and insulin-like growth factors (including insulin-like growth factor 1 [IGF-1], IGF binding protein-1 [IGFBP-1], IGF binding protein-3 [IGFBP-3], leptin) will be measured by a blood draw at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
          <population>11 patients are excluded for missing baseline blood samples.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leptin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.09" spread="1.21"/>
                    <measurement group_id="O2" value="-0.54" spread="1.19"/>
                    <measurement group_id="O3" value="-2.56" spread="1.33"/>
                    <measurement group_id="O4" value="-0.20" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGF-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="2.98"/>
                    <measurement group_id="O2" value="8.22" spread="2.94"/>
                    <measurement group_id="O3" value="-2.66" spread="3.28"/>
                    <measurement group_id="O4" value="-3.05" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.57"/>
                    <measurement group_id="O2" value="0.09" spread="0.56"/>
                    <measurement group_id="O3" value="-1.20" spread="0.63"/>
                    <measurement group_id="O4" value="0.78" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGFBP-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-178.8" spread="82.0"/>
                    <measurement group_id="O2" value="53.4" spread="80.7"/>
                    <measurement group_id="O3" value="25.9" spread="90.2"/>
                    <measurement group_id="O4" value="-96.9" spread="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of leptin in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of IGFBP_1 in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of IGFBP_1 in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Leptin in combined arm is greater than the exercise-only or metformin-only arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Leptin in combined arm is greater than the exercise-only or metformin-only arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose Level</title>
        <description>Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting Glucose level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting Glucose levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
        <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
        <population>11 patients are excluded for missing baseline blood samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise Training With Metformin</title>
            <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
          </group>
          <group group_id="O2">
            <title>Exercise Training</title>
            <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Educational information
Educational information: educational information</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose Level</title>
          <description>Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting Glucose level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer. Fasting Glucose levels in blood will be drawn at baseline, 3 months and 6 months. Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
          <population>11 patients are excluded for missing baseline blood samples.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="2.11"/>
                    <measurement group_id="O2" value="2.93" spread="2.08"/>
                    <measurement group_id="O3" value="-4.11" spread="2.32"/>
                    <measurement group_id="O4" value="4.92" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Glucose in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Glucose in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Body Composition by Treatment Arm - Weight</title>
        <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
        <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
        <population>2 patients are excluded for missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise Training With Metformin</title>
            <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
          </group>
          <group group_id="O2">
            <title>Exercise Training</title>
            <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Educational information
Educational information: educational information</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Body Composition by Treatment Arm - Weight</title>
          <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
          <population>2 patients are excluded for missing baseline measurements.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="0.53"/>
                    <measurement group_id="O2" value="0.70" spread="0.54"/>
                    <measurement group_id="O3" value="-0.91" spread="0.57"/>
                    <measurement group_id="O4" value="1.97" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Weight in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Weight in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Weight in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Body Composition by Treatment Arm - BMI</title>
        <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
        <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
        <population>2 patients are excluded for missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise Training With Metformin</title>
            <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
          </group>
          <group group_id="O2">
            <title>Exercise Training</title>
            <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Educational information
Educational information: educational information</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Body Composition by Treatment Arm - BMI</title>
          <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
          <population>2 patients are excluded for missing baseline measurements.</population>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.20"/>
                    <measurement group_id="O2" value="0.27" spread="0.20"/>
                    <measurement group_id="O3" value="-0.33" spread="0.21"/>
                    <measurement group_id="O4" value="0.70" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of BMI in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of BMI in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of BMI in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Body Composition by Treatment Arm - Waist to Hip Ratio</title>
        <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
        <time_frame>0 and 3 months (change between 0 and 3 months)</time_frame>
        <population>2 patients are excluded for missing baseline measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Exercise Training With Metformin</title>
            <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
          </group>
          <group group_id="O2">
            <title>Exercise Training</title>
            <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Educational information
Educational information: educational information</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Body Composition by Treatment Arm - Waist to Hip Ratio</title>
          <description>Negative least square means indicate a decrease at 3 month comparing to baseline value.</description>
          <population>2 patients are excluded for missing baseline measurements.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.01"/>
                    <measurement group_id="O2" value="0.006" spread="0.01"/>
                    <measurement group_id="O3" value="0.012" spread="0.01"/>
                    <measurement group_id="O4" value="0.016" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: decrease of Waist to Hip Ratio in treatment arm is greater than the control arm.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>One-sided un-adjusted p-values to test if the decrease in treatment arm is greater than the control arm. Holm's method was performed for multiple comparisons to provide an overall significance level of 5%. Only significant p-values were reported.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>An intention-to-treat analysis, with a mixed model that was adjusted for baseline outcome value, BMI (&lt; 30 or &gt; 30), gender, cancer, and study site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Mortality was recorded for all patients. Non serious adverse events were collected for patients treated with Metformin (two arms: Exercise Training With Merformin, and Metformin only).</desc>
      <group_list>
        <group group_id="E1">
          <title>Exercise Training With Metformin</title>
          <description>Exercise training with exercise physiologist with oral metformin
Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID</description>
        </group>
        <group group_id="E2">
          <title>Exercise Training</title>
          <description>Exercise training with exercise physiologist
Exercise training: Two supervised exercise sessions per week</description>
        </group>
        <group group_id="E3">
          <title>Metformin</title>
          <description>Metformin
Metformin: Oral metformin QD for two weeks, then BID</description>
        </group>
        <group group_id="E4">
          <title>Control</title>
          <description>Educational information
Educational information: educational information</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Abdomen Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngeal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited sample size, higher than anticipated dropout, short duration of therapy</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Meyerhardt, Jeffrey,M.D.,M.P.H.</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-6855</phone>
      <email>Jeffrey_Meyerhardt@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

